News

The chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]

APN-1607 is undergoing a global phase 3 trial to evaluate its efficacy as an early diagnostic biomarker for progressive supranuclear palsy.

The associate professor of neurology at Harvard Medical School discussed how clinicians face the challenging decision with their patients in choosing between off-label and approved medications for NMOSD. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Susan W. Broner, MD, the medical director of the Weill Cornell Medicine Headache Program, talked about the essentials of diagnosing and treating various headache disorders from a general neurology perspective.

Avidity Biosciences anticipates to provide new cohort data from the phase 1/2 EXPLORE44 trial assessing AOC 1044 in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the second half of 2024.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Huntington disease.

Sean Pittock, MD, director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval.

BIIB105, an antisense oligonucleotide, failed to demonstrate impact on outcomes of function, breathing, and strength, in addition to no impact on neurofilament light.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024.

A panel of experts provided a new update on practice guidelines for prescribing antiseizure medications to patients with epilepsy who may have a pregnancy.

Voyager expects insights from the phase 1a study to inform a subsequent phase 1b trial and anticipates tau PET imaging data in 2026.

The associate professor in the department of radiology at NYU Langone provided perspective on the unanswered questions regarding neuronal microstructure in migraine following her presentation at the 2024 AAN Annual Meeting. [WATCH TIME: 4 minutes]

Labeling updates underscore the importance of using compatible autoinjectors with specific glatiramer acetate injection products to prevent medication errors.

The study found that Black, Asian, and Hispanic individuals have 7- to 4-fold higher incidence of anti-NMDAR encephalitis, a rare epileptic condition, than White individuals.

Solid Biosciences is expecting to provide initial safety data on SGT-003 from the first couple of pediatric patients with Duchenne muscular dystrophy enrolled in the phase 1/2 INSPIRE Duchenne trial in mid-2024.

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

In honor of Huntington Disease Awareness Day, held May 15, 2024, get caught up on some of the latest news in HD, with data updates and expert insights all in one place from the NeurologyLive® team.

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

Victor Sung, MD, PhD, director of the UAB Huntington’s Disease Clinic, provided perspective on some of the advances and areas of unmet on Huntington Disease Awareness Day.

The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]

The subcutaneous autoinjector, which facilitates 360 mg weekly maintenance dosing of lecanemab, takes less time to administer than the approved intravenous formulation and may lead to less hospital visits and nursing care.

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]

The director of the MedStar Georgetown Headache Center talked about results from an analysis on the DELIVER study assessing response rates of eptinezumab in patients with migraine over an 18-month period.

Treatment with rozanolixizumab was safe among patients with CIDP, resulted in reduced immunoglobulin levels as expected, but did not have an impact on efficacy.

A recent network analysis of clinical trials demonstrated that ravulizumab exhibited greater efficacy in preventing relapse in patients with NMOSD compared with other treatments.

The professor of neurological surgery at Weill Cornell medicine talked about the regulatory hurdles and challenges in patient selection and delivery methods for gene therapy in Parkinson disease. [WATCH TIME: 5 minutes]